<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098249</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00383</org_study_id>
    <nct_id>NCT05098249</nct_id>
  </id_info>
  <brief_title>Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia</brief_title>
  <official_title>Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia Before Elective Surgery - the DeFICIT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Donat R. Spahn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a confirmatory trial to establish superior serum phosphate stability associated with&#xD;
      use of Phoscap® compared with placebo as a supplement for treatment of iron deficiency or&#xD;
      iron deficiency anemia with Ferinject® before elective surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron deficiency anemia is a global health problem most commonly caused by excessive blood&#xD;
      loss, impaired intestinal iron absorption, or chronic inflammation. In the perioperative&#xD;
      setting, intravenous ferric carboxymaltose allows efficient treatment of preoperative iron&#xD;
      deficiency and anemia. Recent studies have implied that ferric carboxymaltose might cause&#xD;
      hypophosphatemia. Notably, hypophosphatemia has been associated with less muscle strength,&#xD;
      which may influence early post-surgery recovery of patients. Additional oral phosphate&#xD;
      supplementation may alleviate this hypophosphatemia.&#xD;
&#xD;
      This is a confirmatory trial to establish superior serum phosphate stability associated with&#xD;
      use of Phoscap® compared with placebo as a supplement for treatment of iron deficiency or&#xD;
      iron deficiency anemia with Ferinject® before elective surgery.&#xD;
&#xD;
      This is also a confirmatory trial to establish non-inferior efficacy of Phoscap® compared&#xD;
      with placebo for the treatment of iron deficiency or iron deficiency anemia with Ferinject®;&#xD;
      and to establish superior core muscle strength associated with the use of Phoscap® compared&#xD;
      with placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2021</start_date>
  <completion_date type="Anticipated">October 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish superior serum phosphate stability</measure>
    <time_frame>3 years</time_frame>
    <description>The primary endpoint is superior serum phosphate stability. The investigators measure perioperative phosphate concentrations in participants during the follow-up visits and compare the results between verum and placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative hemoglobin concentration</measure>
    <time_frame>3 years</time_frame>
    <description>Mean perioperative Hb of the day of surgery, post-operative day (POD)2 and POD4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core muscle strength</measure>
    <time_frame>3 years</time_frame>
    <description>Pre- and postoperative assessment of core muscle strength by volitional testing of maximal inspiratory and expiratory pressures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Anemia</condition>
  <condition>Iron-deficiency</condition>
  <condition>Hypophosphatemia</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verum</intervention_name>
    <description>The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature (Appendix 5: Informed Consent Form)&#xD;
&#xD;
          -  Male or female ASA 1 to 3 patients, at least 18 years old&#xD;
&#xD;
          -  Scheduled for an elective major abdominal or thoracic surgery.&#xD;
&#xD;
          -  Patients with isolated iron deficiency (defined as hemoglobin concentration (Hb) &gt; 130&#xD;
             g/l, and plasma Ferritin &lt; 100 ng/ml or TSAT &lt; 20%), or iron deficiency anemia&#xD;
             (defined as Hb 100-130 g/l, and plasma Ferritin &lt; 100 ng/ml or TSAT &lt; 20%).&#xD;
&#xD;
          -  Patients scheduled to be hospitalized ≥ 3 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known anaphylactic reactions to parenteral iron products. Patients with&#xD;
             allergy/hypersensitivity to any contents of Ferinject® or Phoscap®.&#xD;
&#xD;
          -  Patients with iron overload or disturbances in utilization of iron (e.g.&#xD;
             haemochromatosis, hemosiderosis).&#xD;
&#xD;
          -  Patients with ≥3 times increase in aspartate aminotransferase or alanine&#xD;
             aminotransferase as per reference range.&#xD;
&#xD;
          -  Patients with excessive blood loss requiring massive transfusion (≥ 10 more red blood&#xD;
             cell units).&#xD;
&#xD;
          -  Patients with known myelodysplastic syndromes.&#xD;
&#xD;
          -  Patients with chronic kidney disease with an estimated GFR &lt; 30 ml/min or with&#xD;
             end-stage renal disease requiring scheduled dialysis.&#xD;
&#xD;
          -  Patients with known urinary tract infections with urea-splitting bacteria.&#xD;
&#xD;
          -  Patients with known diseases influencing phosphate, calcium or vitamin D homeostasis&#xD;
             (e.g. Hyperparathyroidism, X-linked hypophosphatemia, renal tubular acidosis).&#xD;
&#xD;
          -  Patients taking medication significantly influencing phosphate, calcium or vitamin D&#xD;
             homeostasis (e.g. vitamin D substitution &gt; 800 I.E. per day in the last 4 months,&#xD;
             pre-existing phosphate substitution, phosphate binders).&#xD;
&#xD;
          -  Patients with preexisting hypophosphatemia&#xD;
&#xD;
          -  Any patient judged to lack the ability to give informed consent or perform the trial&#xD;
             assessments (e.g. due to dementia, insufficient knowledge of the German language).&#xD;
&#xD;
          -  Women who are pregnant or breast feeding,&#xD;
&#xD;
          -  Intention to become pregnant during the course of the study,&#xD;
&#xD;
          -  Lack of safe contraception, defined as: Female participants of childbearing potential,&#xD;
             not using and not willing to continue using a medically reliable method of&#xD;
             contraception for the entire study duration, such as oral, injectable, or implantable&#xD;
             contraceptives, or intrauterine contraceptive devices, or who are not using any other&#xD;
             method considered sufficiently reliable by the investigator in individual cases&#xD;
             (Female participants who are surgically sterilized / hysterectomized or&#xD;
             post-menopausal for longer than 2 years are not considered as being of child bearing&#xD;
             potential),&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse.&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study.&#xD;
&#xD;
          -  Any patient judged by the Principal Investigator or Sub-Investigator to be&#xD;
             inappropriate for the trial for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donat R Spahn, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Kaserer, PD Dr.</last_name>
    <phone>+41442551111</phone>
    <email>alexander.kaserer@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donat R Spahn, Prof. Dr.</last_name>
    <phone>+41432532695</phone>
    <email>donat.spahn@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Muñoz M, Gómez-Ramírez S, Campos A, Ruiz J, Liumbruno GM. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus. 2015 Jul;13(3):370-9. doi: 10.2450/2015.0014-15. Epub 2015 Jun 16. Review.</citation>
    <PMID>26192787</PMID>
  </results_reference>
  <results_reference>
    <citation>Muñoz M, Laso-Morales MJ, Gómez-Ramírez S, Cadellas M, Núñez-Matas MJ, García-Erce JA. Pre-operative haemoglobin levels and iron status in a large multicentre cohort of patients undergoing major elective surgery. Anaesthesia. 2017 Jul;72(7):826-834. doi: 10.1111/anae.13840. Epub 2017 Apr 6.</citation>
    <PMID>28382661</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013 Aug;28(8):1793-803. doi: 10.1002/jbmr.1923.</citation>
    <PMID>23505057</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Donat R. Spahn</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>iron-deficiency anemia</keyword>
  <keyword>hypophosphatemia</keyword>
  <keyword>elective surgery</keyword>
  <keyword>iron-deficiency</keyword>
  <keyword>preoperative iron substitution</keyword>
  <keyword>phosphate substitution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

